# A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

> **NCT06115135** · PHASE2 · RECRUITING · sponsor: **Oncotherapeutics** · enrollment: 39 (estimated)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory

## Interventions

- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06115135
- **Lead sponsor:** Oncotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-20
- **Primary completion:** 2026-04-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06115135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06115135, "A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06115135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*